HIMSS TV is your Insider’s Guide to everything HIMSS. We are the world’s first online broadcasting network, focused on global innovation and how information and technology are driving change in healthcare.
  Home
Advantages of digital therapeutics to pharma
Digital Therapeutics Alliance Summit 2024

Advantages of digital therapeutics to pharma

9:23

Felix Lee, head of organizational capability and transformation at Sanofi, relays how the pharma company leverages DarioHealth's digital therapeutics to complement its drug offerings and gather a comprehensive picture of a patient's health.

Read More
Read Less

Digital Therapeutics Alliance Summit 2024 - Similar Videos View more in Digital Therapeutics Alliance Summit 2024

3:53

Examining the efficacy of digital health solutions

Meg Barron, Peterson Health Technology Institute's managing director of engagement and outreach, relays how the organization independently evaluates digital health offerings' clinical efficacy, budget impact, and return on investment.

Examining the efficacy of digital health solutions
Meg Barron, Peterson Health Technology Institute's managing director of engagement and outreach, relays how the organization independently evaluates digital health offerings' clinical efficacy, budget impact, and return on investment.
3:53
7:05

Teaching neurodiverse individuals using VR

Vijay Ravindran, CEO of Floreo, discusses how virtual reality is particularly beneficial for teaching individuals with neurodiverse issues social and life skills and how investment in extended reality-based digital therapeutics has evolved.

Teaching neurodiverse individuals using VR
Vijay Ravindran, CEO of Floreo, discusses how virtual reality is particularly beneficial for teaching individuals with neurodiverse issues social and life skills and how investment in extended reality-based digital therapeutics has evolved.
7:05
5:49

Digital therapeutics in Canada versus the U.S.

Amos Adler, founder, and president at Memotext, discusses his company's flagship digital app for the schizophrenia and psychosis population and how its portal helps caregivers engage with patients and identify the risks for relapse and readmission.

Digital therapeutics in Canada versus the U.S.
Amos Adler, founder, and president at Memotext, discusses his company's flagship digital app for the schizophrenia and psychosis population and how its portal helps caregivers engage with patients and identify the risks for relapse and readmission.
5:49